Hemp Manufacturing and FDA Compliance: The Batch Record Standard You Need Before the Rules Are Finalized

The FDA has not finalized its regulatory framework for hemp-derived CBD products. This is a fact that hemp manufacturers know well, and one that gets interpreted in two very different ways.

The first interpretation: the rules aren't set, so there's no point building compliance infrastructure until the FDA decides what it actually wants.

The second interpretation: the FDA has signaled clearly that hemp products will eventually be regulated as supplements or food ingredients under existing frameworks — which means the manufacturers who have been building GMP-compliant operations and complete batch records will be positioned to comply quickly, and the ones who haven't will face a significant disruption.

The second interpretation is the correct one. And the specific documentation the FDA has indicated it cares about — regardless of how the final rule reads — is batch records.

What the FDA Has Actually Said About Hemp

The FDA's position on hemp-derived CBD has been consistent since the 2018 Farm Bill: CBD cannot be lawfully marketed as a dietary supplement or added to food under current law because it was first approved as a drug (Epidiolex). The FDA has acknowledged that this creates a gap, committed to working toward a regulatory pathway, and in the meantime continued issuing warning letters to companies making disease claims or selling products with THC levels above 0.3%.

What this means for manufacturers: you are operating in a space where the FDA has not fully defined the rules but has clearly indicated intent to regulate. The enforcement that has happened has focused on product claims and THC compliance. The enforcement that comes next — when the regulatory framework is finalized — will focus on manufacturing quality documentation.

The manufacturers who treat the current regulatory ambiguity as an invitation to skip documentation infrastructure are creating a problem they will have to solve under pressure rather than under their own timeline.

Why GMP Documentation Matters Now, Before It's Required

Good Manufacturing Practices for dietary supplements are defined under 21 CFR Part 111. If hemp-derived CBD products are ultimately regulated as dietary supplements — which is the direction that most regulatory observers expect — 21 CFR Part 111 documentation requirements will apply. Here is what those requirements actually demand from a batch records perspective:

Master Manufacturing Records

For every product you manufacture, you need a Master Manufacturing Record (MMR) that specifies the formula with ingredient quantities per batch size, the name and weight of each ingredient, theoretical yield, and step-by-step manufacturing instructions. This is the template from which individual batch records are created.

For hemp products, the MMR needs to account for cannabinoid variability. If your product is a 25mg CBD tincture and your hemp extract varies between 60% and 80% CBD potency by lot, your MMR needs to specify how the quantity of extract is adjusted based on incoming lot potency to consistently deliver 25mg per serving.

Batch Production Records

For every production run, you need a Batch Production Record (BPR) that captures:

• The actual quantity of each ingredient used (not just the theoretical quantity from the MMR)
• The lot number of each ingredient used
• The identity of the operator who performed each step
• The identity of the person who reviewed each step
• Actual yield versus theoretical yield
• Any deviations from the MMR and their disposition

For hemp manufacturers, the BPR is where your THC compliance documentation lives at the production level. Which lot of hemp extract was used, what its cannabinoid profile showed, and how the quantity was adjusted to hit the target potency — this is the audit trail that demonstrates systematic quality control rather than batch-specific luck.

Laboratory Records

Finished product testing results need to be maintained as laboratory records linked to the specific batch they test. The records need to include: the name of the testing laboratory, the date of testing, the methods used, and the results for each analyte tested.

This is where many hemp manufacturers have documentation that exists but is not structured correctly. The test results are in an email. The batch record is in a separate system. The lot number appears in both, but there is no systematic linkage. When the FDA asks for the laboratory records for batch number X, you should be able to produce them immediately — not after a search through email archives.

The Specific Documentation Risks in Hemp Manufacturing

Beyond the standard GMP documentation requirements, hemp manufacturing has several category-specific documentation challenges.

Source documentation for licensed hemp

Hemp must be grown by a licensed producer under a state or USDA hemp program. The license documentation for your hemp source is part of your raw material supply chain documentation. If the hemp used in your product was grown by an unlicensed producer, your product contains a controlled substance regardless of the THC level.

For manufacturers buying hemp extract rather than raw flower, the chain extends to the extract supplier's source documentation. Your extract supplier should be providing documentation of the licensed farm source for their input material. If they cannot or will not provide this, that is a supply chain risk that belongs in your records.

Delta-8, delta-9, and total THC documentation

The 0.3% THC threshold in the Farm Bill refers to total THC — the sum of delta-9 THC and THCA converted to delta-9 equivalent. Products that test compliant for delta-9 THC alone may exceed the threshold when total THC is calculated.

Your batch records and finished product COAs need to document total THC methodology specifically. The lot number of the hemp extract used, the COA for that lot showing total THC, and the finished product COA confirming total THC compliance in the finished format are the documentation chain that establishes compliance.

For delta-8 THC products — which are derived through chemical conversion of CBD and occupy a legally disputed space — the documentation requirements are more complex. Some states have banned delta-8 entirely. Federal legality is contested. Batch records for delta-8 products should document the conversion process, the starting material, and the testing methodology with particular care, because these records will be the defense if the product's legality is challenged.

Pesticide and contaminant documentation

Hemp is a bioaccumulator — it pulls contaminants from soil efficiently. Hemp grown in contaminated soil can contain elevated levels of heavy metals, pesticides, and other contaminants that concentrate in the extract. The FDA's contamination concerns about hemp products are real, and finished product testing that shows clean results is only part of the story.

The documentation chain that protects you: the farm-level documentation showing the growing conditions and any pesticide applications, the COA for the raw hemp extract including pesticide residue and heavy metals panels, and the finished product COA confirming that the finished format meets safety standards. If a contamination issue is ever raised about your product, having this chain allows you to identify where in the supply chain the issue originated — and demonstrate that your manufacturing process did not introduce the contamination.

What a CBD Manufacturing Inspection Would Look Like Today

The FDA has not routinely inspected hemp supplement manufacturers under GMP requirements because the regulatory framework is not finalized. But the agency has inspected hemp manufacturers under other authorities — adulteration, mislabeling, drug claims — and those inspections have revealed what documentation gaps look like in practice.

Common findings in hemp manufacturer inspections and warning letters:

• No batch records or batch records that are incomplete (missing lot numbers, missing operator identity, no actual-versus-theoretical comparison)
• Finished product testing results that cannot be tied to specific production batches
• No receiving inspection records for incoming hemp extract
• MMRs that do not account for cannabinoid variability between lots
• No deviation records when products are out of specification or production doesn't go to plan

Every one of these findings is a documentation problem with a documentation solution. None of them require a pharmaceutical quality team to fix. They require a consistent system for capturing the right information at the right time and linking it together by batch number.

Building Compliance Infrastructure Ahead of the Rule

The manufacturers who will be positioned best when the FDA finalizes its hemp regulatory framework are the ones who have been operating as if the rules already apply. Not because they are being cautious to a fault, but because compliant documentation practices are also good business practices — they make quality incidents manageable, retail audits straightforward, and consumer complaints resolvable with evidence rather than uncertainty.

Batch Buddy was built for manufacturers who need GMP-compliant documentation without a pharmaceutical-scale quality operation. For hemp manufacturers specifically:

Master Manufacturing Records with potency adjustment logic. When you build a formula in Batch Buddy, you specify the target cannabinoid potency per serving. When a production run uses a hemp extract lot with a specific assay value, the system calculates the adjusted quantity needed to hit target potency based on the lot's actual CBD percentage. The adjustment is documented in the batch record automatically.

Lot traceability from licensed source through finished goods. Every ingredient lot has a receiving record that captures supplier, lot number, and COA. Production batches reference specific ingredient lots. Finished goods reference production batches. The complete chain is retrievable by any lot number in seconds — exactly the documentation an FDA inspector would want to see.

Batch records that capture actuals, not just formula. Operators document actual quantities, lot numbers, and completion confirmations in real time during production. By the time the batch is complete, the record is complete. No reconstruction, no gaps.

FDA 21 CFR Part 11 compliant audit trail. Every record creation, change, and approval is logged with user identity and timestamp. Records cannot be deleted. This is the audit trail infrastructure that 21 CFR Part 111 will require when it applies to hemp — and it is available now.

The Window for Proactive Compliance Is Still Open

The regulatory uncertainty in hemp is real. So is the direction of travel: toward more documentation requirements, not fewer. The manufacturers who build compliant operations now will have a genuine competitive advantage when the rules are finalized — faster to certify, more credible with retail buyers, and better positioned to scale without a compliance overhaul in the middle of a growth phase.

The manufacturers who wait will face the same build, just under worse conditions.

Batch Buddy provides hemp and supplement manufacturers with FDA 21 CFR Part 11 compliant batch records, potency adjustment tracking, and full lot traceability from source to finished goods. Start your free 14-day trial.